Microbot Medical (NASDAQ:MBOT – Get Free Report) and Sight Sciences (NASDAQ:SGHT – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.
Analyst Ratings
This is a summary of recent ratings and target prices for Microbot Medical and Sight Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Microbot Medical | 0 | 0 | 1 | 0 | 3.00 |
| Sight Sciences | 0 | 5 | 2 | 0 | 2.29 |
Microbot Medical presently has a consensus price target of $9.00, suggesting a potential upside of 508.11%. Sight Sciences has a consensus price target of $4.68, suggesting a potential upside of 77.40%. Given Microbot Medical’s stronger consensus rating and higher possible upside, research analysts plainly believe Microbot Medical is more favorable than Sight Sciences.
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Microbot Medical | N/A | N/A | -$10.74 million | ($0.80) | -1.85 |
| Sight Sciences | $79.54 million | 1.68 | -$55.55 million | ($1.02) | -2.59 |
Microbot Medical has higher earnings, but lower revenue than Sight Sciences. Sight Sciences is trading at a lower price-to-earnings ratio than Microbot Medical, indicating that it is currently the more affordable of the two stocks.
Insider and Institutional Ownership
16.3% of Microbot Medical shares are held by institutional investors. Comparatively, 55.5% of Sight Sciences shares are held by institutional investors. 10.5% of Microbot Medical shares are held by company insiders. Comparatively, 28.9% of Sight Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Microbot Medical and Sight Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Microbot Medical | N/A | -218.30% | -158.17% |
| Sight Sciences | -63.30% | -47.28% | -32.72% |
Volatility & Risk
Microbot Medical has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Sight Sciences has a beta of 2.52, indicating that its stock price is 152% more volatile than the S&P 500.
Summary
Sight Sciences beats Microbot Medical on 7 of the 13 factors compared between the two stocks.
About Microbot Medical
Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
About Sight Sciences
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.
